首页> 外文OA文献 >Efficacy and safety of single agent sunitinib in treating Sorafenib Refractory Advanced Hepatocellular Carcinoma Patients: a prospective, open-label, phase II study

【2h】

Efficacy and safety of single agent sunitinib in treating Sorafenib Refractory Advanced Hepatocellular Carcinoma Patients: a prospective, open-label, phase II study

机译：单药舒尼替尼治疗索拉非尼难治性晚期肝细胞癌患者的疗效和安全性：前瞻性，开放性，II期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Conference Theme: A Bridge to a Consensus on HCC Management

机译：会议主题：达成HCC管理共识的桥梁

著录项

作者
Tang, YF; Cheung, TT; Fan, ST; Poon, RTP; Leung, RCY; Wong, HYH; Chiu, JWY; Chan, P; Pang, RWC; Yau, TCC;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open-label, single-arm phase II study [J] . Vichien SRIMUNINNIMIT, Virote SRIURANPONG Suthida SUWANVECHO Asia-Pacific journal of clinical oncology . 2014,第3期

机译：索拉非尼联合吉西他滨治疗晚期肝细胞癌的疗效和安全性：一项多中心，开放标签，单组II期研究
2. A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma [J] . D. H. Palmer, Y. T. Ma, M. Peck-Radosavljevic, British Journal of Cancer . 2018,第9期

机译：一项多中心，开放标签，I期/随机II期研究，用于评估nintedanib与sorafenib在欧洲晚期肝细胞癌患者中的安全性，药代动力学和疗效
3. A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma [J] . D. H. Palmer, Y. T. Ma, M. Peck-Radosavljevic, British Journal of Cancer . 2018,第9期

机译：一项多中心，开放标签，I期/随机II期研究，用于评估nintedanib与sorafenib在欧洲晚期肝细胞癌患者中的安全性，药代动力学和疗效
4. Diffusion-weighted MR imaging of advanced hepatocellular carcinoma treated with the oral multikinase inhibitor Sorafenib [C] . C. Schraml, N.F. Schwenzer, H. Rempp, World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：口服多激酶抑制剂索拉非尼治疗晚期肝癌的扩散加权MR成像
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. A multicentre open-label phase-I/randomised phase-II study to evaluate safety pharmacokinetics and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma [O] . D. H. Palmer, Y. T. Ma, M. Peck-Radosavljevic, 2018

机译：一项多中心开放标签I期/随机II期研究评估nintedanib与sorafenib在欧洲晚期肝细胞癌患者中的安全性药代动力学和疗效
7. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population [O] . Chok, KSH, Fan, ST, Cheung, TT, 2009

机译：单药索拉非尼治疗乙型肝炎流行亚洲人群晚期肝细胞癌的2期开放性研究

Efficacy and safety of single agent sunitinib in treating Sorafenib Refractory Advanced Hepatocellular Carcinoma Patients: a prospective, open-label, phase II study

摘要

著录项

相似文献

相关主题

期刊订阅